期刊文献+

危险信号分子与原发性肝癌的研究进展 被引量:3

Role of alarmins in the pathogenesis of primary hepatic carcinoma
下载PDF
导出
摘要 危险信号分子,是一大类细胞结构蛋白,病理情况下释放到细胞外,通过启动和介导炎症反应,传递着细胞损伤的危险信号.以HMGB1、HSPs和S100为代表的危险信号分子,在肝脏慢性炎症和肿瘤形成的微环境中持续存在,在原发性肝癌形成和进展过程中发挥着重要的作用.危险信号分子可以成为新的预测和监测原发性肝癌发生、转移和复发的标志物,下调这些危险信号分子表达及阻断其与受体结合的措施,有望成为新的抗肿瘤治疗方法. Alarmins are a kind of constitutive cellular proteins which are released extracellularly under pathological conditions to signal danger to the host by triggering and mediating inflammatory responses.Persistent release of alarmins(e.g.,HMBG1,HSPs and S100)during chronic liver inflammation and in tumor microenvironments plays an important role in the development and progression of liver carcinoma.Alarmins might become novel markers for predicting and monitoring carcinogenesis,metastasis and recurrence of liver carcinoma.Down-regulation of alarmins and blockage of the interaction of alarmins with their receptors represent new promising therapeutic strategies for liver carcinoma.
出处 《世界华人消化杂志》 CAS 北大核心 2011年第13期1326-1330,共5页 World Chinese Journal of Digestology
基金 国家自然科学基金资助项目 No.30972621~~
关键词 危险信号分子 慢性炎症 原发性肝癌 Alarmins Chronic inflammation Primary hepatic carcinoma
  • 相关文献

参考文献33

  • 1Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045 PubMed DOI.
  • 2Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1-5 PubMed DOI.
  • 3Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 2008; 3: 99-126 PubMed DOI.
  • 4Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867 PubMed DOI.
  • 5Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008; 18: 3-10 PubMed DOI.
  • 6Yang GY, Taboada S, Liao J. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. Methods Mol Biol 2009; 511: 193-233 PubMed DOI.
  • 7Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435 PubMed DOI.
  • 8杨秉辉,丛文铭,周晓军,陈孝平,杨甲梅,樊嘉,王建华,杨仁杰,李槐,蒋国梁,曾昭冲,陈敏华,陈敏山,梁萍,吕明德,罗荣城,刘鲁明,秦叔逵,叶胜龙,吴孟超,汤钊猷,孙燕,管忠震.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3):259-269. 被引量:313
  • 9Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799 PubMed DOI.
  • 10Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912 PubMed DOI.

二级参考文献57

  • 1黄庆先,孙念峰,王国斌,王春友.反义核苷酸抑制人高迁移率族蛋白1表达对胰腺癌细胞的影响[J].华中科技大学学报(医学版),2004,33(5):562-565. 被引量:4
  • 2彭建平,范学工,刘洪波.慢性乙型肝炎患者高迁移率族蛋白1mRNA的表达及其临床意义[J].世界华人消化杂志,2006,14(2):167-172. 被引量:23
  • 3刘洪波,范学工,Haichao Wang,彭建萍,黄建军,李宁.人HMGB1基因的克隆、融合表达与生物学活性[J].中国生物工程杂志,2006,26(11):20-23. 被引量:6
  • 4Ellerman JE,Brown CK,de Vera M,et al.Masquerader:high mobility group box-1 and cancer.Clin Cancer Res,2007,13:2836-2848.
  • 5Chung HW,Lee SG,Kim H,et al.Serum high mobility group box-1 (HMGB 1) is closely associated with the clinical and pathologic features of gastric cancer.J Transl Med,2009,7:38.
  • 6Kuniyasu H,Chihara Y,Kondo H.Differential effects between amphoterin and advanced glycation end products on colon cancer cells.Int J Cancer,2003,104:722-727.
  • 7Gnanasekar M,Thirugnanam S,Ramaswamy K.Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1)expression leads to inhibition of prostate cancer cell survival and apoptosis.Int J Oncol,2009,34:425-431.
  • 8UlloaL,MessmerD.High-mobility groupbox 1 (HMGB1)protein:friend and foe.Cytokine Growth Factor Rev,2006,17:189-201.
  • 9Yu M,Wang L Li W,et al.Proteomic screen defines the hepatocyte nuclear factor 1alpha-binding partners and identifies HMGB1 as a new cofactor of HNF1alpha.Nucleic Acids Res,2008,36:1209-1219.
  • 10Taguchi A,Blood DC,del Toro G,et al.Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.Nature,2000,405:354-360.

共引文献352

同被引文献55

  • 1黄卫,杨冬华.肝癌相关基因甲基化的研究进展[J].国外医学(消化系疾病分册),2004,24(4):213-215. 被引量:3
  • 2Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
  • 3Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepato12008; 48 Suppl 1:S20-S37.
  • 4Jemal A, Bray F, Center MM, Ferlay J, Ward E, For- man D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
  • 5Zeng Y. Principles of micro-RNA production and maturation. Oncogene 2006; 25:6156-6162.
  • 6Kloosterman WP, Plasterk RH. The diverse func- tions of microRNAs in animal development and disease. Dev Cell 2006; 11:441-450.
  • 7Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91:827-887.
  • 8Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
  • 9Munker R, Calin GA. MicroRNA profiling in can- cer. Clin Sci (Lond) 2011; 121:141-158.
  • 10Szafranska AE, Davison TS, John J, Cannon T, SiposB, Maghnouj A, Labourier E, Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26:4442-4452.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部